Table 1.
Clinical features and follow-up of patients with ≤ GG3 and ≥ GG4 prostate cancer
| ≤ GG3 | ≥ GG4 | Pvalue | |
|---|---|---|---|
| Patients, no. | 9 | 9 | |
| Age, median (range) | 68 (53–72.4) | 65 (60–74) | 0.8249a |
| Gleason Grade Group, no. (%) | |||
| GG2 | 5 (56%) | 0 | |
| GG3 | 4 (44%) | 0 | |
| GG4 | 0 | 1 (11%) | |
| GG5 | 0 | 8 (89%) | |
| Clinical features, median (range) | |||
| PSA ng/mL | 6.7 (4-11) | 7 (4.3–22.6) | 0.3072a |
| Tumour volume | 4 (0.7-7.1) | 19.7 (0.7–30.2) | 0.0103a |
| Clinical features, no. (%) | |||
| Pathologic T stage 2 | 2 (22%) | 2 (22%) | 1.0b |
| Pathologic T stage 3 | 7 (78%) | 7 (78%) | |
| Positive margins | 6 (67%) | 3 (33%) | 0.6372c |
| Extra-prostatic extension | 7 (78%) | 7 (78%) | 1.0c |
| Seminal vesicle invasion | 3 (33%) | 7 (78%) | 0.1534c |
| Lymph node metastases at diagnosis | 0 | 4 (44%) | 0.0824c |
| Patient follow-upd, no. (%) | |||
| Disease relapsee | 2 (25%) | 8 (89%) | 0.0030e |
| Metastasis | 1 (13%) | 7 (78%) | 0.0152c |
| Castration-resistant prostate cancer | 0 (0%) | 3 (33%) | 0.2059c |
| Death from prostate cancer | 0 (0%) | 1 (11%) | 1.0c |
aUnpaired T test with Welch’s correction
bThe Fisher exact test comparing the proportion of patients with T2 versus T3 disease
cThe Fisher exact test comparing the proportion of patients with or without each clinical feature
dFollow-up information was unavailable for one GG ≤ 3 patient, so n = 8
eDisease relapse includes biochemical or clinical recurrence, HR = 6.937 (1.738–27.68), log rank test